Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Future of cancer vaccines.

Authors
  • Winter, Hauke
  • Fox, Bernard A
  • Rüttinger, Dominik
Type
Published Article
Journal
Methods in Molecular Biology
Publication Date
Jan 01, 2014
Volume
1139
Pages
555–564
Identifiers
DOI: 10.1007/978-1-4939-0345-0_40
PMID: 24619704
Source
Medline
License
Unknown

Abstract

Extensive research in the area of active-specific immunotherapy has led to the approval of the first therapeutic cancer vaccine sipuleucel-T (Provenge™) in 2010. Even though a major milestone for the field of cancer immunotherapy, many obstacles towards successful integration of vaccination strategies into the oncologists' armamentarium remain. This chapter discusses possible future perspectives for cancer vaccines as a treatment modality in oncology with special focus on biomarkers (response prediction and patient selection), requirements for clinical trial design, and combination therapies (standard of care and new molecular entities).Extensive research in the area of active-specific immunotherapy has led to the approval of the first therapeutic cancer vaccine sipuleucel-T (Provenge™) in 2010. Even though a major milestone for the field of cancer immunotherapy, many obstacles towards successful integration of vaccination strategies into the oncologists' armamentarium remain. This chapter discusses possible future perspectives for cancer vaccines as a treatment modality in oncology with special focus on biomarkers (response prediction and patient selection), requirements for clinical trial design, and combination therapies (standard of care and new molecular entities).

Report this publication

Statistics

Seen <100 times